These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19402071)

  • 1. Complexity of tumor vasculature in clear cell renal cell carcinoma.
    Qian CN; Huang D; Wondergem B; Teh BT
    Cancer; 2009 May; 115(10 Suppl):2282-9. PubMed ID: 19402071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications.
    Yao X; Qian CN; Zhang ZF; Tan MH; Kort EJ; Yang XJ; Resau JH; Teh BT
    Clin Cancer Res; 2007 Jan; 13(1):161-9. PubMed ID: 17200351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma.
    Cao Y; Zhang ZL; Zhou M; Elson P; Rini B; Aydin H; Feenstra K; Tan MH; Berghuis B; Tabbey R; Resau JH; Zhou FJ; Teh BT; Qian CN
    Cancer; 2013 Jan; 119(2):313-24. PubMed ID: 22811049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer.
    Mertz KD; Demichelis F; Kim R; Schraml P; Storz M; Diener PA; Moch H; Rubin MA
    Hum Pathol; 2007 Oct; 38(10):1454-62. PubMed ID: 17889675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues.
    Meteoglu I; Erdogdu IH; Meydan N; Erkus M; Barutca S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):53. PubMed ID: 18928570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
    Ebbinghaus SW; Gordon MS
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma.
    Wu L; Li X; Ye L; Shayiremu D; Deng X; Zhang X; Jiang W; Yang Y; Gong K; Zhang N
    Anticancer Res; 2014 Feb; 34(2):715-22. PubMed ID: 24511004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antiangiogenic therapies for renal cell cancer.
    Gordon MS
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
    Eberhard A; Kahlert S; Goede V; Hemmerlein B; Plate KH; Augustin HG
    Cancer Res; 2000 Mar; 60(5):1388-93. PubMed ID: 10728704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microvascular network in renal carcinomas. Quantitative and tissue microarray immunohistochemical study.
    Okoń K; Kawa R
    Pol J Pathol; 2008; 59(2):107-15. PubMed ID: 18669177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of ERK1/2 and prognosis of clear cell renal cell carcinoma.
    Lee HJ; Kim DI; Kang GH; Kwak C; Ku JH; Moon KC
    Urology; 2009 Feb; 73(2):394-9. PubMed ID: 18849062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
    Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
    Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
    [No Abstract]   [Full Text] [Related]  

  • 14. Serous neoplasms of the pancreas share many, but not all aspects of their microvascular and angiogenic profile with low-grade clear cell renal cell carcinomas.
    Liszka Ł; Pająk J; Gołka D
    Pathol Res Pract; 2014 Dec; 210(12):901-8. PubMed ID: 25155377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
    Abrahamson PA
    Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
    [No Abstract]   [Full Text] [Related]  

  • 16. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
    Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
    J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal cell carcinoma: the end of a tunnel?].
    Ravaud A; Dilhuydy MS
    Pathol Biol (Paris); 2006 May; 54(4):206-8. PubMed ID: 16530346
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance to angiogenesis inhibitors in renal cell carcinoma.
    Tamaskar I; Dhillon J; Pili R
    Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal cell carcinoma and prognostic factors].
    Edeline J; Rioux-Leclercq N
    Ann Pathol; 2008 Oct; 28(5):374-80. PubMed ID: 19068392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
    Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
    Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.